IMM.L Stock - ImmuPharma plc
Unlock GoAI Insights for IMM.L
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $118,350 | $126,667 |
| Gross Profit | $-63,880 | $-37,607 | $-118,000 | $118,350 | $126,667 |
| Gross Margin | N/A | N/A | N/A | 100.0% | 100.0% |
| Operating Income | $-2,280,000 | $-3,063,000 | $-3,029,000 | $-6,587,000 | $-5,589,000 |
| Net Income | $-2,483,000 | $-2,922,000 | $-3,807,000 | $-8,174,000 | $-6,860,000 |
| Net Margin | N/A | N/A | N/A | -6906.6% | -5415.8% |
| EPS | $-0.01 | $-0.01 | $-0.01 | $-0.03 | $-0.03 |
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Visit WebsiteEarnings History & Surprises
IMM.LEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 18, 2026 | — | — | — | — |
Q3 2025 | Sep 8, 2025 | — | — | — | — |
Q2 2025 | Jun 3, 2025 | — | — | — | — |
Q2 2025 | May 19, 2025 | — | — | — | — |
Q4 2024 | Dec 31, 2024 | — | $-0.00 | — | — |
Q3 2024 | Sep 9, 2024 | — | $-0.00 | — | — |
Q2 2024 | Jun 5, 2024 | — | $-0.00 | — | — |
Q2 2024 | May 29, 2024 | — | $-0.00 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.00 | — | — |
Q3 2023 | Aug 31, 2023 | — | $-0.00 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.00 | — | — |
Q2 2023 | May 11, 2023 | — | $-0.00 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.01 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.00 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.01 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.00 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.02 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.01 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.01 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.01 | — | — |
Latest News
Frequently Asked Questions about IMM.L
What is IMM.L's current stock price?
What is the analyst price target for IMM.L?
What sector is ImmuPharma plc in?
What is IMM.L's market cap?
Does IMM.L pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to IMM.L for comparison